Comprehensive genetic screens have shown that genetic alterations in glioblastoma are distributed across the entire genome, resulting in the dysregulation of many critical signalling pathways such as the RB and p53 pathways and the receptor tyrosine kinase/Ras/phosphoinositide 3-kinase signalling pathways [7, 8]. The gene discussed is TP53; the disease is glioblastoma.